Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, filed a Form 4 on November 18, 2026, disclosing the exercise of 9,500 stock options and the sale of 9,500 shares of common stock on November 17, 2026, all conducted through a trust and pursuant to a pre-arranged 10b5-1 trading plan.
Key Highlights
- Option exercise: 9,500 stock options were exercised on November 17, 2026, at an exercise price of $117.76 per share, held indirectly through a family trust.
- Shares sold: A total of 9,500 shares of common stock were disposed of across 11 separate sale transactions on November 17, 2026, at weighted average prices ranging from $576.1626 to $586.4854 per share.
- 10b5-1 plan: According to the filing, the transactions were made pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, covering up to 1,734,410 stock options expiring March 15, 2027, with the plan set to end on the earlier of full exercise or December 31, 2026.
- Remaining beneficial ownership: Following the reported transactions, Rothblatt beneficially owned 324,443 shares indirectly through the trust involved in the sales, plus additional holdings across other direct and indirect accounts.
- Remaining options: After the exercise, 5,410 stock options remained beneficially owned indirectly through a family trust, with an expiration date of March 15, 2027.
- Reporting person role: Rothblatt is identified in the filing as both a Director and an Officer (Chairperson and CEO) of United Therapeutics Corp (NASDAQ:UTHR).
Rothblatt's November 17 Option Exercise and Share Sales at United Therapeutics
According to the Form 4 filed with the SEC on November 18, 2026, Martine A. Rothblatt exercised 9,500 stock options on November 17, 2026, at a price of $117.76 per share. The filing states these options were held indirectly through a family trust, described as one "as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries." The options had vested in equal one-third installments on March 15, 2021, 2022, and 2023, and carry an expiration date of March 15, 2027.
On the same date, the filing discloses that 9,500 shares of common stock were sold across 11 separate tranches, also from the same family trust. The weighted average sale prices for those tranches ranged from $576.1626 to $586.4854 per share. Each tranche was executed in multiple trades, and the filing notes that Rothblatt "hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected." All transactions are attributed to a 10b5-1 trading plan adopted on November 7, 2025.
Following all reported transactions, the filing indicates Rothblatt held 324,443 shares indirectly through the trust involved in those sales, with additional holdings of 40,513 shares directly, 166 shares indirectly by spouse, 249,108 shares in separate family trusts where the spouse is sole or co-trustee, 45,596 shares in trusts where the spouse shares investment power, and 8,902 shares in trusts where Rothblatt is sole or co-trustee. A remaining balance of 5,410 stock options was also reported as held indirectly through a family trust.
What Was Disclosed
The filing reports a single-day exercise of 9,500 stock options at $117.76 and the sale of the resulting 9,500 shares at weighted average prices between $576.1626 and $586.4854, all executed through a family trust under an existing 10b5-1 plan.




Please wait processing your request...